Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Weil-Hillman

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Scanning Electron Microscopy|January 1, 1985
Arrest of Daudi cell growth by inactive influenza virus in-vitroG Weil-Hillman, Z Zakay-Rones
Acta Virologica|May 1, 1991
Increase in concanavalin A cap formation on lymphoma cells following interaction with inactive influenza virusesG Weil-Hillman, R Levi, Z Zakay-Rones
Scanning Electron Microscopy|January 1, 1985
Visualization of the fate of inactive influenza viruses in Daudi cells by electron microscopyG Weil-Hillman, H Gamliel, A Friedmann, et al.
Cancer Research|March 1, 1985
Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse modelG Weil-Hillman, W Runge, F K Jansen, et al.
Cancer Research|January 15, 1987
Combined immunochemotherapy of human solid tumors in nude miceG Weil-Hillman, F M Uckun, J M Manske, et al.
Journal of Biological Response Modifiers|October 1, 1988
Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patientsG Weil-Hillman, J A Hank, N S Rosenthal, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivoJ A Hank, G Weil-Hillman, J E Surfus, et al.
Bulletin of the New York Academy of Medicine|January 1, 1989
The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatmentS D Voss, G Weil-Hillman, J A Hank, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|August 1, 1991
Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatmentG Weil-Hillman, K Schell, D M Segal, et al.
Critical Reviews in Oncology/Hematology|January 1, 1989
The cellular immunotherapy of cancer: current and potential uses of interleukin-2P M Sondel, J A Hank, P C Kohler, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Scanning Electron Microscopy|January 1, 1985
Arrest of Daudi cell growth by inactive influenza virus in-vitroG Weil-Hillman, Z Zakay-Rones
Acta Virologica|May 1, 1991
Increase in concanavalin A cap formation on lymphoma cells following interaction with inactive influenza virusesG Weil-Hillman, R Levi, Z Zakay-Rones
Scanning Electron Microscopy|January 1, 1985
Visualization of the fate of inactive influenza viruses in Daudi cells by electron microscopyG Weil-Hillman, H Gamliel, A Friedmann, et al.
Cancer Research|March 1, 1985
Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse modelG Weil-Hillman, W Runge, F K Jansen, et al.
Cancer Research|January 15, 1987
Combined immunochemotherapy of human solid tumors in nude miceG Weil-Hillman, F M Uckun, J M Manske, et al.
Journal of Biological Response Modifiers|October 1, 1988
Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patientsG Weil-Hillman, J A Hank, N S Rosenthal, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivoJ A Hank, G Weil-Hillman, J E Surfus, et al.
Bulletin of the New York Academy of Medicine|January 1, 1989
The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatmentS D Voss, G Weil-Hillman, J A Hank, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|August 1, 1991
Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatmentG Weil-Hillman, K Schell, D M Segal, et al.
Critical Reviews in Oncology/Hematology|January 1, 1989
The cellular immunotherapy of cancer: current and potential uses of interleukin-2P M Sondel, J A Hank, P C Kohler, et al.
Pageof 2